Qadir Rabah, Costales Timothy, Coale Max, Zerhusen Timothy, Joshi Manjari, O'Toole Robert V
Department of Orthopaedics, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD; and.
Division of Infectious Disease, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD.
J Orthop Trauma. 2021 Jan 1;35(1):17-22. doi: 10.1097/BOT.0000000000001855.
To determine whether patients with operatively treated fractures and surgical site infection after use of topical vancomycin powder have a lower proportion of Staphylococcus aureus infections than patients who did not receive topical vancomycin powder.
Retrospective cohort study.
Level I trauma center.
Treatment group: 10 of 133 patients (145 fractures) with surgical site infections who received intrawound vancomycin powder at the time of wound closure for fracture fixation. Control group: 175 patients who sustained deep surgical site infections during the same period but did not receive vancomycin powder.
Vancomycin powder or no vancomycin powder.
Proportion of patients' cultures positive for S. aureus.
The proportion of cultures positive for S. aureus was significantly lower in patients with surgical site infection who received vancomycin powder than in those who did not receive vancomycin powder (10% [1 of 10 patients in the treatment group] vs. 50% [87 of 175 patients in the control group]; P = 0.02). A trend was observed for a lower proportion of methicillin-resistant S. aureus (0% vs. 23%; P = 0.12).
Vancomycin powder might alter the bacteriology of surgical site infections and decrease the proportion in culture of the most common organism typically present after fracture surgery infection. These findings suggest that the application of vancomycin powder might change the bacteriology of surgical site infections when they occur, regardless of the effect on overall infection rates. Although our bacteriology results are clinically and statistically significant, these findings must be confirmed in larger randomized controlled trials.
Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
确定使用局部万古霉素粉末治疗骨折后发生手术部位感染的患者,其金黄色葡萄球菌感染比例是否低于未接受局部万古霉素粉末治疗的患者。
回顾性队列研究。
一级创伤中心。
治疗组:133例手术部位感染患者中的10例(145处骨折),这些患者在骨折固定伤口闭合时接受了伤口内万古霉素粉末治疗。对照组:同期发生深部手术部位感染但未接受万古霉素粉末治疗的175例患者。
万古霉素粉末或不使用万古霉素粉末。
金黄色葡萄球菌培养阳性患者的比例。
接受万古霉素粉末治疗的手术部位感染患者中,金黄色葡萄球菌培养阳性比例显著低于未接受万古霉素粉末治疗的患者(10%[治疗组10例患者中的1例]对50%[对照组175例患者中的87例];P = 0.02)。耐甲氧西林金黄色葡萄球菌比例有降低趋势(0%对23%;P = 0.12)。
万古霉素粉末可能改变手术部位感染的细菌学情况,并降低骨折手术后感染中通常出现的最常见病原体的培养比例。这些发现表明,无论对总体感染率的影响如何,万古霉素粉末的应用可能改变手术部位感染发生时的细菌学情况。虽然我们的细菌学结果在临床和统计学上具有显著性,但这些发现必须在更大规模的随机对照试验中得到证实。
治疗性III级。有关证据水平的完整描述,请参阅作者须知。